What Specialty Access Looks Like When It’s Built to Scale

Sponsored by CoverMyMeds

Industry expert Miranda Delatore, DNP, RN, NEA‑BC, of CoverMyMeds, explores the critical challenges biopharma manufacturers face in getting patients started on specialty therapies and what a truly connected access strategy looks like.

Fragmentation across benefits investigation, prior authorization, and enrollment has long forced clinical teams to enter data across multiple disconnected systems, creating costly errors and delays. Delatore makes the case that a connected specialty access and affordability solution that integrates eligibility, authorization, and patient services into a single ecosystem is no longer a nice-to-have, but a core capability that must scale with a manufacturer's pipeline.

Delatore discusses how real-time data visibility across providers, pharmacies, payers, and patient support programs can eliminate rework, reduce follow-up phone calls between stakeholders, and most importantly, shorten the time to therapy for patients. She challenges biopharma manufacturers to move beyond treating access as an administrative afterthought and instead embed it into their core workflow and strategic planning, arguing that this shift will be a key differentiator in the years ahead.